Fulgenzi v. Pliva, Inc., et al.

Filing 168

Memorandum Opinion: Defendant PLIVA's motion for summary judgment (Doc. No. 102 ) is granted. This case is dismissed. Judge Sara Lioi on 10/23/2015. (P,J)

UNITED STATES DISTRICT COURT
NORTHERN DISTRICT OF OHIO
EASTERN DIVISION

ELEANOR FULGENZI,

PLAINTIFF,
vs.
PLIVA, Inc.,

DEFENDANT.

)
)
)
)
)
)
)
)
)
)
)

CASE NO. 5:09-cv-1767

JUDGE SARA LIOI

MEMORANDUM OPINION

In this pharmaceutical products liability action, plaintiff Eleanor Fulgenzi
(“plaintiff” or “Fulgenzi”) alleges that she developed the severe neurological movement disorder
tardive dyskinesia (“TD”) after ingesting metoclopramide. The remaining defendant, PLIVA,
Inc. (“defendant” or “PLIVA”), a manufacturer of a generic version of metoclopramide (which is
known by the name brand of Reglan), moves for summary judgment on the sole surviving cause
of action, a failure-to-warn claim brought under Ohio statutory law. (Doc. No. 102 [“MSJ”].)
Plaintiff opposes the motion (Doc. No. 126 [“Opp’n”]), and PLIVA has filed a reply. (Doc. No.
129 [“Reply”].)
I. BACKGROUND
A.

Prescription Drug Regulatory Background

While plaintiff’s failure-to-warn claim is brought under Ohio law, it is necessary
to first set forth the federal regulatory scheme governing the manufacture and distribution of
prescription medication as it serves as the backdrop, and in some sense sets the boundaries, for
plaintiff’s claim. Pursuant to the Food, Drug, and Cosmetic Act (“FDCA”), 21 U.S.C. § 301 et.

seq., the FDA is charged with the responsibility of approving new drugs. See 21 U.S.C. § 355(a);
Riegel v. Medtronic, Inc., 552 U.S. 312, 315, 128 S. Ct. 999, 169 L. Ed. 2d 892 (2008); Merck
KGaA v. Integra Lifesciences I, Ltd., 545 U.S. 193, 196, 125 S. Ct. 2372, 162 L. Ed. 2d 160
(2005). A manufacturer seeking to market a new drug must file a New Drug Application
(“NDA”) with the FDA. 21 U.S.C. § 355(b). As part of its application, the manufacturer must
demonstrate through pre-market trials and other relevant evidence that the drug is safe, and that
the proposed labeling properly sets forth the correct dosage and possible risks. The NDA
requires, among other things, that the manufacturer supply the agency with “full reports of
investigations which have been made to show whether or not such drug is safe for use and
whether such drug is effective in use[]” and “specimens of the labeling proposed to be used for
such drug[.]” § 355(b)(1).
In contrast, drug manufacturers seeking to market a generic drug must file an
Abbreviated New Drug Application (“ANDA”). The ANDA procedure, codified as amended in
the Hatch-Waxman Act, 21 U.S.C. § 355(j)(2)(A), sets forth an expedited review process. To
obtain approval, the manufacturer must demonstrate that the generic drug it seeks to market is
approved as a listed drug, meaning that the new drug is the functional equivalent of a namebrand drug already approved by the FDA. 21 U.S.C. § 355(j)(2)(A)(iv). “One of the benefits to
manufacturers who opt for the ANDA procedure is that they are required only to conduct
‘bioequivalency’ studies that establish that the generic and the reference-listed drug are
pharmaceutically equivalent[.]” Stacel v. Teva Pharm., USA, 620 F. Supp. 2d 899, 905 (N.D. Ill.
2009). So long as the manufacturer can demonstrate that the generic drug is the pharmaceutical
equivalent of its name-brand counterpart, the generic manufacturer need not duplicate the pre-

2

market trials conducted by the name-brand manufacturer. This advantage serves the purpose of
the Hatch-Waxman Act to increase the availability of low cost generic drugs. See id. at 907.
Federal regulations further require that a generic drug’s “[l]abeling (including the
container label, package insert, and, if applicable, Medication Guide) proposed for the drug
product must be the same as the labeling approved for the reference listed drug, except for
changes required because of differences approved under a petition filed under § 314.93 or
because the drug product and the reference listed drug are produced or distributed by different
manufacturers.” 21 C.F.R. § 314.94(a)(8)(iv). The FDA can reject an ANDA application if the
information submitted by the generic manufacturer is “insufficient to show that the labeling
proposed for the drug is the same as the labeling approved for the listed drug[.]” 21 C.F.R. §
314.127(a)(7).
Thus, name-brand drug manufacturers and the manufacturers of the name-brand’s
generic counterpart face different sets of obligations with respect to their labels. Name-brand
manufacturers must prove that the proposed label is “accurate and adequate.” 21 U.S.C. §
355(b)(1), (d); PLIVA, Inc. v. Mensing, --U.S.--, 131 S. Ct. 2567, 2574, 180 L. Ed. 2d 580
(2011). The manufacturers of generic medications, on the other hand, are not independently
required to demonstrate the accuracy or adequacy of their labels. Instead, generic drug
manufacturers are obligated to ensure that their proposed warning label is identical to the label of
the corresponding name-brand drug. This is sometimes referred to as the duty of “sameness.” See
Morris v. PLIVA, Inc., 713 F.3d 774, 776 (5th Cir. 2013).

3

B.

Reglan and its Generic Counterpart

Reglan, the reference listed drug (“RLD”) for metoclopramide, was first approved
by the FDA in 1980, and has been traditionally prescribed to treat a variety of digestive illnesses,
including “symptomatic gastroesophageal reflux and acute diabetic gastric stasis.” (Doc. No. 60
(Second Amended Complaint [“SAC”]) ¶ 19.) In the years following Reglan’s introduction,
post-marketing studies revealed the risk of developing TD from the product’s use. Patients with
TD typically present with symptoms that include involuntary and uncontrollable movements of
the head, neck, and face, as well as grotesque facial grimacing and tongue thrusting. In light of
the acquired knowledge of the increased risk of developing TD from the use of Reglan, the
brand-name’s package insert was changed in 1985 to include a warning that TD may develop in
patients treated with metoclopramide. Specifically, the insert warned that the development of
symptoms associated with neurological diseases like TD was likely to occur in 1 in 500 patients
treated with metoclopramide. (Doc. No. 102-4 (1985 Physicians’ Desk Reference [“PDR”] for
Reglan Label) at 33761.)
In 1987, the labeling for Reglan/metoclopramide was revised to include
information that provided that use of metoclopramide was indicated for “short-term (4 to 12
weeks) therapy for adults with symptomatic, documented gastroesophageal reflux who fail to
respond to conventional therapy.” (Doc. No. 102-5 (1987 Label for Metoclopramide) at 3381.)
Further, the Dosage and Administration section, advised, in relevant part, that: “[t]herapy for
longer than 12 weeks has not been evaluated and cannot be recommended.” (Id.)
Another significant labeling change, relating to the duration of treatment with the

1

All page number references are to the page identification number generated by the Court’s electronic docketing
system.
4

drug, took place in 2004 when the FDA approved the name-brand manufacturer’s request to add
the following bolded statements directly under the heading in the Indications and Usage section
of the package insert: “The use of reglan® tablets is recommended for adults only. Therapy
should not exceed 12 weeks in duration.” The approved revision also provided for a similar
bolded sentence directly under the heading of the Dosage and Administration section: “Therapy
with reglan® tablets should not exceed 12 weeks in duration.” (Doc. No. 102-3 (2004 Reglan
label) at 3366, 3372.) For purposes of the present summary judgment motion, it is undisputed
that PLIVA failed to revise its generic label for metoclopramide to include the 2004 updated
sentences, even though the duty of “sameness” imposed by federal regulation required PLIVA to
do so.
In 2009, the FDA announced that it would approve further changes to the warning
on the Reglan label, as well as the addition of a black-box warning—the strongest warning
sanctioned by the FDA—that “[t]reatment with metoclopramide can cause tardive dyskinesia, a
serious movement disorder that is often irreversible. . . . Treatment with metoclopramide for
longer than 12 weeks should be avoided in all but rare cases.” Mensing, 131 S. Ct. at 2572.
C.

Plaintiff’s Treatment History with Metoclopramide

Plaintiff was prescribed Reglan by three different physicians, for varying lengths
of time, between July 2004 and August 2007. (SAC ¶ 17; Doc. No. 103-15 (Expert Report of
Richard M. Trosch, M.D.) at 3929; see also Doc. No. 103-1 (Memorandum in Support of Motion
to Strike Dr. Trosh’s Testimony [“Mot. to Strike”]) at 3677 and supporting exhibits.) While each
physician wrote prescriptions for the brand name Reglan, it is undisputed that a pharmacist filled
each prescription with the generic equivalent.

5

1.

Dr. Shameem M. Ahmed

In July 2004, Dr. Ahmed, a board certified gastroenterologist, diagnosed plaintiff
with gastroparesis after an EGD revealed “[l]arge amounts of undigested food” throughout her
stomach.2 (Doc. No. 102-15 (Office Visit Notes of Dr. Ahmed) at 3438-3440.) He wrote plaintiff
four prescriptions for Reglan between July 22, 2004 and September 30, 2004, and two more
prescriptions for Reglan on August 10, 2006 and September 21, 2006. (Mot. to Strike at 3677
and supporting exhibits; see also Doc. No. 102-20 (Excerpts from the Deposition of Dr. Ahmed
[“Ahmed Dep. I”]) at 3525.) The first three prescriptions were filled with generic
metoclopramide manufactured by Teva, Inc. (Mot. to Strike at 3677.) The two prescriptions
issued in 2006 were filled with metoclopramide manufactured by Mutual.3 (Id.) Only the
prescription written on September 30, 2004 was filled with metoclopramide manufactured by
PLIVA. (Id.) In February 2005, Dr. Ahmed discontinued this medication after he determined that
plaintiff’s symptoms were not improving. (Dr. Ahmed Depo. at 8289-90, 8325.) For reasons that
are not entirely clear from the record, Dr. Ahmed restarted plaintiff on Reglan in 2006.
In his deposition, Dr. Ahmed testified that he had been familiar with the name-

2

The record also demonstrates that plaintiff has suffered and/or continues to suffer from myriad other medical
ailments and conditions, including: depression, anxiety, chronic diarrhea, breast cancer, shingles with post-herpetic
neuropathy, migraines, hypertension, hiatal hernia, obesity, restless leg syndrome, insomnia, allergic rhinitis,
chronic renal insufficiency/failure, and osteoarthritis. (Doc. No. 102-8 (Lake Hospital System Medical Notes); Doc.
No. 102-9 (Dr. Lackey Medical Notes); Doc. No. 102-10 (Lake Health Preoperative Record); Doc. No. 102-11
(Urology Inc. Questionnaire); Doc. No. 102-12 (Crystal Clinic Medical Notes); Doc. No. 102-13 (Aetna Records);
Doc. No. 102-14 (Lake Health Summary).)
3

It is worth noting that Mutual’s package insert contained the 2004 warning. (Doc. No. 102-6 (Affidavit of Robert
Dettery) ¶¶ 4-5.)

6

brand drug Reglan since the mid-1970’s when he was a medical student. (Id. at 8301.) He
explained that, when a new medication is released, he tries to read the available literature on it,
including the package inserts from the manufacturers. (Id. at 8302.) He further explained that,
“once you get used to [the drug, however], there is a comfort level that you develop . . . .”4 (Id.)
Having such a comfort level with Reglan, he is unsure whether he reviewed the packaging
information for it, and, in any event, he testified that he did not review the package insert or
labeling for Reglan prior to prescribing it for plaintiff. (Id.) He also testified that he had never
heard of PLIVA, or ever reviewed any written materials about metoclopramide from PLIVA,
though he indicated that he knew that when a prescription is written for a brand name drug, the
generic equivalent may be dispensed. (Id. at 8303-04.) Rather, he maintained that he relied on his
clinical experience and his past knowledge of Reglan in prescribing it for plaintiff. (Id.)
Nonetheless, he also testified that he has “changed significantly” his use of
Reglan since the time of plaintiff’s treatment. (Id. at 8315.) He testified that he rarely prescribes
it for elderly patients, and he documents informed consent with all patients who receive a
prescription for it. (Id. at 8316.) Additionally, when asked if the 2004 warning that
metoclopramide was not to be used beyond twelve weeks would have affected him if it had been
brought to his attention, he replied: “It would have, but, again, you know, with everything that’s
going around us now, we are still using the medicine after proper informed consent.” (Id. at
8319.) Likewise, when asked if his use of the drug would have changed if the 2004 warning had
been brought to his attention earlier, he responded “Probably to some degree, yes.” (Id. at 8320.)
4

Dr. Ahmed testified candidly that what “commonly happens with newer, high—you know, medications that are
coming out with what we call biologics and things like that, so—but on the other hand, doctors are really lazy, and
not everything that comes across your desk you read it. I honestly tell you, there’s so much material that comes in.
Have I looked at everything? Probably not. So I—I can’t answer you, what is my expectations in terms of a very old
medicine like that.” (Dr. Ahmed Depo. at 8333-34.)
7

2.

Dr. Erica Sobolewski

Dr. Sobelowski, a family practice physician who served as plaintiff’s primary care
physician from May 2004 until January 2007, wrote five prescriptions for Reglan, one in
September 2004 and four between September 2006 and June 2007. (Mot. to Strike at 3677.) Dr.
Sobolewski was the physician who had referred plaintiff to Dr. Ahmed, and the first prescription
for Reglan she wrote for plaintiff was, in essence, a renewal or continuation of Dr. Ahmed’s
prescriptions, which Dr. Sobolewski agreed to fill for plaintiff as a courtesy. (Doc. No. 126-26
(Excerpts from the Deposition of Dr. Sobolewski [“Sobolewski Dep.”]) at 8238, 8241-43, 8246.)
All of Dr. Sobolewski’s prescriptions were filled with generic metoclopramide manufactured by
PLIVA. (Mot. to Strike at 3677.)
In her deposition, Dr. Sobolewski testified that, at the time she first prescribed
Reglan for plaintiff, she was generally familiar with the drug and knew that it had been around
for a long time. (Sobolewski Dep. at 8249.) She stated that she did not recall ever reviewing a
package insert for the brand name Reglan, or any generic metoclopramide product. (Id. at 825657.) In particular, when asked, “prior to writing that prescription for Mrs. Fulgenzi in September
of 2004 for Regan, did you ever read any label or package insert for a generic metoclopramide
product manufactured by PLIVA, Inc.,” she responded “No, not that I recall.” (Id. at 8257.)
Like Dr. Ahmed, Dr. Sobolewski testified that at some point after she treated
plaintiff, she became more acutely aware of the link between metoclopramide and TD. (Id. at
8268.) While she was not sure that she had read the 2009 “black box” warning issued by the
manufacturer of Reglan and/or the manufacturers of generic metoclopramide, she believes that
around the general time of this warning, she changed her perception of the drug. (Id. at 8270.)
According to Dr. Sobolewski, if she had been advised in 2004 that the warning for
8

metoclopramide had been revised to provide that therapy should not exceed twelve weeks, it
would have affected her use of the drug in her practice. (Id. at 8272-74.)
3.

Dr. Michael V. Baranauskas

Dr. Baranauskas has served as plaintiff’s primary care physician since May 29,
2007, after plaintiff’s treatment with Dr. Sobolewski ended. (Doc. No. 126-28 (Excerpts from the
Deposition of Dr. Baranauskas [“Baranauskas Dep.”]) at 8344, 8353.) He testified that when he
first saw plaintiff, she reported that her major medical complaint related to her depression. Dr.
Baranauskas responded by making adjustments to certain medications. (Id. at 8360.) At her
second visit, on July 31, 2007, plaintiff reported that she believed she was having problems
tolerating the medication Effexor, as she was experiencing oral and extrapyramidal-type
movements, tongue, jaw, and grinding of her teeth. (Id. at 8363-64.) Believing these problems to
be associated with plaintiff’s treatment with Effexor, Dr. Baranauskas discontinued that
medication. (Id. at 8365-67.)
A month later (August 2007), Dr. Baranauskas received a request from plaintiff’s
mail-in prescription company to refill plaintiff’s prescription of Reglan. Dr. Baranauskas
complied with the request, and approved a 90 day supply of Reglan, which the pharmacist filled
with metoclopramide manufactured by PLIVA. (Id. at 8373-76, 8398-99; Mot. to Strike at 3677.)
In connection with this prescription, Dr. Baranauskas testified that he had received some
information from the pharmacist that called into question the dose of metoclopramide plaintiff

9

was receiving.5 He further testified that the pharmacist provided some information about
metoclopramide, which addressed age-related concerns and potential adverse outcomes including
TD, and Dr. Baranauskas reviewed this information and his office discussed dosing levels with
plaintiff before he signed off on the prescription.6 (Baranauskas Dep. at 8382-8385.)
He did not, however, review any labeling or package inserts from any generic
manufacturer of metoclopramide prior to prescribing Reglan for plaintiff, and he stated that he
did not even know the names of any of the generic manufacturers. (Id. at 8399-8400.) He may
have reviewed the package insert or the PDR for the brand name Reglan at some point in the
past, but he did not review it before prescribing it for plaintiff. (Id. at 8399, 8404.) Nonetheless,
he was certain that he has never reviewed any labeling or package inserts for a metoclopramide
product sold by PLIVA. (Id. at 8399-8401.) And while he did not know at the time he prescribed
Reglan for plaintiff that long-term use substantially increased the risk of developing movement
disorders like TD, he subsequently came to appreciate this connection, which has caused him to
effectively discontinue prescribing the medication in his practice. (Id. at 8410-13.) Had the 2004
label change been brought to his attention, he surmises that it would have “potentially” caused
him to reevaluate his decision to prescribe it for plaintiff. (Id. at 8418.)

5

In her opposition brief, plaintiff represents that the “pharmacy contacted Dr. Baranauskas questioning the dosage
of metoclopramide prescribed to Ms. Fulgenzi, as it exceeded the maximum dosage recommended in PLIVA’s
label.” (Opp’n at 7917 (citing Doc. No. 102-39)). The Court has carefully reviewed the exhibit from the pharmacy in
question—Medco—and there is no indication that the pharmacy’s information came from PLIVA or its package
insert. The document includes the prescription, which was written for the name-brand Reglan, and provides some
“prescribing information” about the drug. The only indication of where this information came from is in the section
entitled “References” which identifies two medical journals. (Id. at 3662.)
6

Dr. Baranauskas was not the only prescribing physician to receive inquiries from pharmacists regarding plaintiff’s
Reglan prescriptions. Dr. Sobolewski testified that plaintiff’s pharmacy sent correspondence to her office, noting
that plaintiff suffered from depression, underscoring the fact that depression is a known side effect of
metoclopramide, and questioning the dosage that plaintiff had been prescribed. (Doc. No. 102-27 (Excerpts from
Deposition of Dr. Sobolewski [“Sobolewski Dep. I”]) at 3579-3580.) It is undisputed that none of the pharmacy
inquires touched upon the information contained in the 2004 warning relating to duration of treatment with
Reglan/metoclopramide.
10

D.

Plaintiff is Diagnosed with TD

Dr. Baranauskas referred plaintiff to a psychiatrist after discontinuing plaintiff’s
Effexor did not resolve her involuntary movement issues, and plaintiff was eventually seen by
Dr. Bahman Sharif. (Baranauskas Dep. at 8366-67; Doc. No. 126-29 (Excerpts from the
Deposition of Dr. Sharif [“Sharif Dep.”]) at 8437-38.) Upon examination of plaintiff, Dr. Sharif
determined that she should discontinue her use of metoclopramide, and he subsequently had
discussions with Dr. Baranauskas about starting plaintiff on a plan to ween her off
metoclopramide. (Sharif Dep. at 8443-45.) Dr. Sharif diagnosed plaintiff with TD caused by her
long-term exposure to Reglan. (Id. at 8458, 8460.) Other physicians have reached similar
conclusions about the origins of plaintiff’s movement disorder. (Doc. No. 126-31 (Excerpts from
the Deposition of Dr. Lewitt [“Lewitt Dep.”]) at 8484; Baranauskas Dep. at 8416.)
E.

Plaintiff’s Lawsuit

On July 30, 2009, plaintiff brought suit in federal court against certain
manufacturers of generic metoclopramide and brand name Reglan, raising a variety of state law
tort claims, including defective design, breach of warranties, fraud, misrepresentation, and
intentional infliction of emotional distress. (Doc. No. 1 (Complaint).) At the core of all of
plaintiff’s claims was the basic assertion that the drug manufacturers should have provided
warnings alerting doctors and patients to the heightened risk of developing neurological
complications from long-term use of metoclopramide. On January 25, 2010, plaintiff dismissed
with prejudice all claims against the manufacturers of the brand name Reglan after it was
determined that plaintiff had only ingested generic metoclopramide (Doc. No. 27 (Stipulation).)
At the request of the remaining parties, this Court stayed the action pending a
ruling from the United States Supreme Court on the question of whether regulations promulgated
11

by the FDA relating to the labeling of generic medication preempt state laws that may require
generic drug manufacturers to provide more stringent safety warnings on their products. (Doc.
No. 57 (Order).) On June 23, 2011, the Supreme Court issued its decision in Mensing, wherein
the Supreme Court found it impossible for PLIVA, as a manufacturer of generic
metoclopramide, “to comply with both their state-law duty to change the label and their federal
duty to keep the label the same.” Mensing, 131 S. Ct. at 2578. The Supreme Court held federal
law preempts “state tort-law claims based on certain drug manufacturers’ alleged failure to
provide adequate warning labels for generic metoclopramide.” Id. at 2572.
Following the ruling in Mensing, this Court granted plaintiff leave to file an
amended complaint. Included in her causes of action was a failure-to-warn claim under the Ohio
Product Liability Act (“OPLA”), Ohio Rev. Code § 2307.76. (SAC at 1987-89.) On March 31,
2012, the Court granted PLIVA’s motion to dismiss plaintiff’s claims. In its decision, the Court
found some claims abrogated by the OPLA, and others to be insufficiently pled under Rule 8 of
the Federal Rules of Civil Procedure. Ultimately, the Court determined that “all of the claims,
including those otherwise abrogated by the OPLA, hinge on the warnings the drug manufacturers
gave, or from Plaintiff’s perceptive, failed to give.” (Doc. No. 67 (Opinion and Order) at 2429.)
Accordingly, the Court determined that “regardless of how Plaintiff attempts to cast these claims,
they are, at the core, failure-to-warn claims that are clearly preempted by Mensing.” (Id. at
2428.)
On appeal (which was limited to this Court’s ruling only as to plaintiff’s product
liability claims based on the 2004 failure to update), the Sixth Circuit rejected PLIVA’s
argument that plaintiff’s claims were preempted on grounds of impossibility, to the extent that
plaintiff’s failure-to-warn allegations were limited to PLIVA’s failure to communicate the
12

warning contained in the 2004 revision, as such a warning was allowed (and even required)
under federal regulations. See Fulgenzi v. PLIVA, Inc., 711 F.3d 578, 584 (6th Cir. 2013). In so
ruling, the court carefully defined the contours of plaintiff’s surviving claim:
We note at this point that Fulgenzi’s claims survive only to the extent PLIVA’s
actions were permitted by federal law. She cannot claim that PLIVA should have
included an aggressive black-box warning: any such allegations are preempted
under Mensing. Instead, she is left to argue only that PLIVA’s warning was
inadequate to the extent that it did not include the language contained in the
updated Reglan label from 2004. This leaves her with a weaker case than if she
were suing a branded-drug manufacturer, but that is the statutory scheme provided
to us by Congress. See Mensing, 131 S.Ct. at 2582.
Id. at 584 (emphasis in original).
Going forward, the Sixth Circuit cautioned that plaintiff’s claim(s) “must pass
through the ‘narrow gap’” between emerging Supreme Court preemption law, “and will be
constrained as a result. The arguments [plaintiff] makes, the proofs she offers, and the evidence
she submits are all subject to limitation by preemption principles. Under Mensing, Fulgenzi’s
claims are viable only to the extent PLIVA’s actions were permitted by federal law.” Id. at 588
(internal citation omitted). Ultimately, the court concluded that plaintiff “must argue that PLIVA
should have included the language contained in the updated Reglan label by soon after July
2004, and that the failure to include that language proximately caused her injuries.”7 Id.

7

While the Sixth Circuit emphasized that plaintiff could not rely on the fact that PLIVA’s failure to include the 2004
updated warning violated federal law to support her state law failure-to-warn claim, see id. at 587, it observed that
“[f]ederal standards are . . . likely to arise in determining the adequacy of PLIVA’s warning, since FDA approval
and industry practices may be relevant to the state duty of care.” Id. at 588-89.
13

II. SUMMARY JUDGMENT STANDARD
When a party files a motion for summary judgment, it must be granted “if the
movant shows that there is no genuine dispute as to any material fact and the movant is entitled
to judgment as a matter of law.” Fed. R. Civ. P. 56(a). “A party asserting that a fact cannot be or
is genuinely disputed must support the assertion by: (A) citing to particular parts of materials in
the record . . . ; or (B) showing that the materials cited do not establish the absence or presence
of a genuine dispute, or that an adverse party cannot produce admissible evidence to support the
fact.” Fed. R. Civ. P. 56(c)(1).
In reviewing summary judgment motions, this Court must view the evidence in a
light most favorable to the non-moving party to determine whether a genuine issue of material
fact exists. Adickes v. S.H. Kress & Co., 398 U.S. 144, 157, 90 S. Ct. 1598, 26 L. Ed. 2d 142
(1970); White v. Turfway Park Racing Ass’n, Inc., 909 F.2d 941, 943-44 (6th Cir. 1990),
impliedly overruled on other grounds by Salve Regina Coll. v. Russell, 499 U.S. 225, 111 S. Ct.
1217, 113 L. Ed. 2d 190 (1991). A fact is “material” only if its resolution will affect the outcome
of the lawsuit. Anderson v. Liberty Lobby, Inc., 477 U.S. 242, 248, 106 S. Ct. 2505, 91 L. Ed. 2d
202 (1986). Determination of whether a factual issue is “genuine” requires consideration of the
applicable evidentiary standards. Thus, in most civil cases the Court must decide “whether
reasonable jurors could find by a preponderance of the evidence that the [non-moving party] is
entitled to a verdict[.]” Id. at 252.
Summary judgment is appropriate whenever the non-moving party fails to make a
showing sufficient to establish the existence of an element essential to that party’s case and on
which that party will bear the burden of proof at trial. Celotex Corp. v. Catrett, 477 U.S. 317,
322, 106 S. Ct. 2548, 91 L. Ed. 2d 265 (1986). Moreover, “[t]he trial court no longer has the duty
14

to search the entire record to establish that it is bereft of a genuine issue of material fact.” Street
v. J.C. Bradford & Co., 886 F.2d 1472, 1479-80 (6th Cir. 1989) (citing Frito-Lay, Inc. v.
Willoughby, 863 F.2d 1029, 1034 (D.C. Cir. 1988)). The non-moving party is under an
affirmative duty to point out specific facts in the record as it has been established that create a
genuine issue of material fact. Fulson v. City of Columbus, 801 F. Supp. 1, 4 (S.D. Ohio 1992).
The non-movant must show more than a scintilla of evidence to overcome summary judgment; it
is not enough for the non-moving party to show that there is some metaphysical doubt as to
material facts. Id. (citation omitted).
III. ANALYSIS
A.

Plaintiff States a Failure-to-Warn Claim under Ohio Law

In support of summary judgment, PLIVA argues, first, that plaintiff has fallen
short of properly stating a “failure-to-warn” claim under Ohio statutory law. (MSJ at 3342.)
Section 2307.76(A)(1) of the Ohio Revised Code provides that a product is defective due to
inadequate warning under the OPLA when:
(a)

The manufacturer knew or, in the exercise of reasonable care, should have
known about a risk that is associated with the product and that allegedly
caused harm for which the claimant seeks to recover compensatory damages;
[and]

(b)

The manufacturer failed to provide the warning or instruction that a
manufacturer exercising reasonable care would have provided concerning that
risk, in light of the likelihood that the product would cause harm of the type
for which the claimant seeks to recover compensatory damages and in light of
the likely seriousness of that harm.
To establish a failure-to-warn claim under the OPLA, a plaintiff must prove each

of the following: “(1) a duty to warn against reasonably foreseeable risks; (2) breach of this duty;
and (3) an injury that is proximately caused by the breach.” Monroe v. Novartis Pharm. Corp.,
15

29 F. Supp. 3d 1115, 1125 (S.D. Ohio 2014) (quoting Graham v. Am. Cyanamid Co., 350 F.3d
496, 514 (6th Cir. 2003)). A warning is considered adequate “only if ‘it reasonably discloses all
inherent risks, and if the product is safe when used as directed.’” McConnell v. Cosco, Inc., 238
F. Supp. 2d 970, 976 (S.D. Ohio 2003) (quoting Phan v. Presrite Corp., 653 N.E.2d 708, 711
(Ohio Ct. App. 1994) and citing Restatement (Second) of Torts § 402A cmt. j).
While its argument is not entirely clear, PLIVA appears to posit that plaintiff’s
statutory failure-to-warn claim is fatally deficient because the alleged omitted warning—that
treatment with metoclopramide should not exceed 12 weeks—fails to identify the risk associated
with the product; namely, the risk of developing TD. (MSJ at 3343.) Yet, the Sixth Circuit
rejected a similar argument of PLIVA’s that an inadequate omitted warning could not serve as
the basis for a failure-to-warn claim under the OPLA. Specifically, the court observed:
PLIVA also tries to argue that there is no such thing as a “failure-to-inadequatelywarn” claim under Ohio law. Appellee Br. at 30. To start, Fulgenzi’s complaint
does not have to be read as asserting such a claim. While her allegation that any
warning short of the FDA’s 2009 “black-box” warning was unreasonable is
preempted, she is free to argue in the alternative that any label lacking Reglan’s
2004 updated warning was inadequate. Further, there is nothing in the Ohio
product-liability law inconsistent with a claim that a defendant failed to warn,
even inadequately. In a failure-to-warn case, the plaintiff must show that “[t]he
manufacturer failed to provide the warning or instruction that a manufacturer
exercising reasonable care would have provided.” Ohio Rev. Code § 2307.76.
Since Fulgenzi alleges that the non-updated warning used by PLIVA in 2004 does
not meet the standard of reasonable care, this element is satisfied.
Fulgenzi, 711 F.3d at 587 (emphasis in original). In so ruling, the court observed that “[i]t may
well be more difficult to prove proximate causation in a case where the warning that the
defendant failed to provide was also legally inadequate. But there is no reason to believe that a
severely inadequate warning would never cause an injury that a moderately inadequate warning
would have prevented.” Id.
16

Here, of course, PLIVA would have been precluded by its federal duty of
“sameness” to add to the 2004 warning by explaining that the 12 week treatment limit was
necessitated by a concern that long-term use of metoclopramide could lead to neurological
disorders, such as TD. Still, even if federal regulations would have left the 2004 warning
arguably inadequate under the OPLA, plaintiff remains free to attempt to show that use of this
inadequate warning would have prevented her neurological injuries.
In any event, the question of whether plaintiff’s second amended complaint stated
a claim under the OPLA was foreclosed by the Sixth Circuit’s ruling, which provided:
Thus Fulgenzi does not fail to properly state a claim. Fulgenzi alleges that
PLIVA’s use of the old warning (“Therapy longer than 12 weeks has not been
evaluated and cannot be recommended.”) instead of adding the updated one
(“Therapy should not exceed 12 weeks in duration.”) was unreasonable, and
the proximate cause of her injuries. At the motion-to-dismiss stage, it is
sufficiently plausible that the use of a neutral warning disavowing approval
instead of a bold-faced warning affirmatively discouraging long-term use
proximately caused Fulgenzi’s injury. Whether in fact these allegations are true is
a matter for further proceedings.
Id. at 588 (bolding in original). Plaintiff’s claim survives PLIVA’s initial argument in support of
summary judgment.
B.

Plaintiff Cannot, as a Matter of Law, Establish Proximate Cause

Of course, at the summary judgment stage, a plaintiff must do more than merely
offer complaint allegations that state a cause of action. As the Sixth Circuit alluded to in its order
of remand, the ultimate question in this case is whether PLIVA’s failure to update its label in
2004 to include the bolded warning that “[t]herapy should not exceed 12 weeks in duration[]”
was the proximate cause of plaintiff’s injuries. According to PLIVA, plaintiff cannot meet this
element of her failure-to-warn claim, and summary judgment, in its favor, is warranted. In
support, PLIVA advances a number of (lack of) proximate cause arguments, two of which are as
17

follows:8 First, according to PLIVA, the learned intermediary doctrine bars plaintiff’s claim.
Recognized under Ohio law, and codified at Ohio Rev. Code § 2307.76(C), the learned
intermediary doctrine provides that a drug manufacturer satisfies its duty to warn of known risks
by providing an adequate warning to the medical professional of the risks associated with the
drug’s use. Vaccariello v. Smith & Nephew Richards, Inc., 763 N.E.2d 160, 164 (Ohio 2002)
(quotation marks and citation omitted). But the Court need not determine whether this doctrine
applies because PLIVA’s second argument—that proximate cause is lacking because the record
shows that plaintiff’s prescribing physicians did not rely upon PLIVA’s deficient 2004 warning
label—is dispositive.
The undisputed facts in the record establish that plaintiff’s physicians did not ever
read, let alone rely on, PLIVA’s inadequate 2004 warning. As set forth above, proximate cause is
an essential element that plaintiff must establish in order to prevail on her Ohio failure-to-warn
claim. See Graham, 350 F.3d at 514. “A plaintiff ‘not only must convince the fact finder that the
warning provided is unreasonable, hence inadequate, but he also must establish the existence of
proximate cause between the [product] and the fact of the plaintiff[’]s injury.’” Miller v. ALZA
Corp., 759 F. Supp. 2d 929, 936 (S.D. Ohio 2010) (quoting Hisrich v. Volvo Cars of N. Am.,
Inc., 226 F.3d 445, 450-51 (6th Cir. 2000)) (further citation omitted). “‘In analyzing the
proximate cause issue as it relates to failure-to-warn cases,’ the Ohio Supreme Court ‘divided
proximate causation . . . into two sub-issues: (1) whether the lack of adequate warnings

8

PLIVA also offers other arguments in support of summary judgment, including: that it did not nor should not have
reasonably known of the risks associated with its product, that there is no evidence that it failed to act with
reasonable care, and that plaintiff cannot establish that her injuries were the result of ingesting generic
metoclopramide. The Court need not address these issues, which, in any event, appear to involve disputed issues of
fact, because plaintiff’s inability to establish genuine issues of material fact as to proximate causation necessitates
summary dismissal of her failure-to-warn claim.
18

contributed to the plaintiff’s [use of the product], and (2) whether [use of the product]
constitute[d] a proximate cause of the plaintiff’s injury.’” Hisrich, 226 F.3d at 451 (quoting Seley
v. G.D. Searle Co., 423 N.E.2d 831, 838 (Ohio 1981)).
Under Ohio law, there exists “a presumption that if an adequate warning is given
it will be read and heeded, which benefits the manufacturer.” Monroe, 29 F. Supp. 3d at 1125
(citing, among authorities, Restatement (Second) of Torts § 402A cmt. j.) In contrast, where an
inadequate warning is given, the presumption favors the plaintiff. Id. (“That is, the failure to
adequately warn was a proximate cause of the plaintiff’s ingestion of the drug.”) (quotation
marks and citation omitted). “However, a defendant can rebut this presumption by showing that
‘an adequate warning would have made no difference in the physician’s decision as to whether to
prescribe a drug or as to whether to monitor the patient thereafter.’” Id. (quoting Seley, 423
N.E.2d at 838).
PLIVA indirectly argues that any presumption in favor of proximate cause
resulting from its inadequate warning is rebutted by the fact that plaintiff’s prescribing
physicians cannot say that they ever read a PLIVA package insert for metoclopramide—adequate
or otherwise. “Indeed, the inadequacy of a warning cannot be the proximate cause of a plaintiff’s
injuries if the user of the product failed to read the warnings accompanying the product. Even if
such a warning were adequate, it could not prevent the harm if the user did not read the
warning.” McConnell, 238 F. Supp. 2d at 978 (citing Hisrich, 226 F.3d at 451) (applying Ohio
law); see Web v. Smith, No. 18859, 1998 WL 801944, at *5 (Ohio Ct. App. Nov. 18, 1998)
(“Because nobody read or relied on the warning, any alleged inadequacy in the warning was not
the proximate cause for Webb’s injury.”) Consequently, an inadequate warning in a prescription
package insert cannot be the proximate cause of a resulting injury if the physician did not read
19

the insert prior to prescribing the medication. See, e.g., Pustejovsky v. Pliva, Inc., 623 F.3d 271,
277 (5th Cir. 2010) (because physician did not recall ever reading the inadequate warning in the
2004 package insert for metoclopramide, the warning could not be the proximate cause of his
patient’s injuries); Motus v. Pfizer Inc., 196 F. Supp. 2d 984, 996 (C.D. Cal. 2001) (because the
physician did not read the package insert for Zoloft until after his patient committed suicide, “the
inclusion of adequate warnings in that information would not have affected his decision” to
prescribe the medication).
Dr. Ahmed testified that he has never reviewed any prescribing information from
PLIVA for its metoclopramide product, and had never even heard of PLIVA. (Ahmed Dep. at
8302-03.) Dr. Baranauskas testified that, at the time he prescribed Reglan, he did not review a
PLIVA metoclopramide package insert. (Baranauskas Dep. at 8400.) Dr. Sobolewski testified
slightly less definitively when responding to the question of whether she had reviewed the
PLIVA warning by adding to her “no” the qualifier “not that I recall.” (Sobolewski Dep. at
8257.) Still, all three doctors stated that they did not read the PLIVA warning. This uncontradicted testimony demonstrates that an adequate warning would have made no difference
and sufficiently rebuts the presumption that the inadequacy of the warning was the proximate
cause of plaintiff’s injuries.9 Of course, plaintiff was not foreclosed from pointing to contrary

9

Plaintiff appears to suggest that the causal connection between PLIVA’s inadequate warning and her injuries can
be made through the pharmacies that communicated with Drs. Baranauskas and Sobolewski regarding the dosage of
Reglan these doctors prescribed. (See Opp’n at 7928 (“As Ms. Fulgenzi’s physicians indicated their reliance upon
pharmacists for relevant information, the evidence establishes that the instructions and warnings provided to these
physicians by PLIVA was not only inadequate, it was nonexistent.”) The record simply does not support plaintiff’s
representation that the information that prompted the pharmacies’ inquires was taken from a PLIVA insert. As the
Court has already observed, the correspondence from Medco gives no indication that the information in its flyer
came from PLIVA, and, in fact, it cites other sources for its information on metoclopramide. (Doc. No. 102-39 at
3662.) Likewise, the correspondence from Rational Med to Dr. Sobolewski also fails to mention PLIVA and cites
other sources for its information on the drug. (Doc. No. 102-26 at 3569.) Plaintiff cannot use guesswork and
speculation to oppose a properly supported summary judgment motion.
20

evidence in the record that would suggest that these physicians did read and rely upon PLIVA’s
inadequate warning, but she has failed to do so.10 Consequently, she has not demonstrated the
existence of a genuine issue of material fact as to proximate cause, and PLIVA is entitled to
summary judgment.11 See Seley, 423 N.E.2d at 839 (“Where, as here, an adequate warning would
have made no difference in the physician’s decision as to whether to prescribe a drug or as to
whether to monitor the patient thereafter, the presumption established by Comment j is rebutted,
and the required element of proximate cause between the warning and ingestion of the drug is
lacking.”)
Of course, it is not surprising that none of plaintiff’s prescribing physicians
reviewed the PLIVA insert. The record establishes that the physicians had varying degrees of
knowledge of the risks associated with Reglan at the time they prescribed the drug for plaintiff,
and may (or may not) have reviewed the 2004 package insert provided by the manufacturers of
Reglan. (Ahmed Dep. at 8302-03 [relied on clinical experience and past knowledge but did not
rely on 2004 Reglan warning]; Sobolewski Dep. at 8257-58 [did not recall reading 2004 Reglan
warning]; and Baranauskas Dep. at 8403-04, 8410 [may have previously read package insert or

10

To the extent that Dr. Sobolewski’s guarded testimony could be construed as leaving open the possibility that she
simply does not remember whether she read the warning, it is true that “[h]er lack of memory, of course, does not
preclude the possibility that she had read these materials, neither can it sustain [plaintiff’s] burden.” See Pustejovsky,
623 F.3d at 277 (summary judgment appropriately granted to generic drug manufacturer where physician testified
that she did not recall ever reading the package insert for the drug and the plaintiff came forward with no evidence
that might have indicated that her doctor did rely on the insert in prescribing the drug). Plaintiff did not come
forward with any evidence that would have created a factual dispute on this point.
11

Plaintiff’s failure-to-warn claim asserts that PLIVA “failed to adequately warn consumers and/or their health care
providers” of the “significant risks of serious bodily harm, including but not limited [to] Tardiv Dysknesia . . . .”
(Doc. No. 60 (Second Amended Complaint [“SAC”]) ¶ 119, emphasis added.) The SAC further alleges that
“[p]laintiff and/or her prescribing health care providers relied upon the inadequate warning labels when prescribing
and/or ingesting Reglan/Metoclopramide.” (Id. ¶ 128.) However, the record before this Court on summary judgment
demonstrates that plaintiff, like her physicians, did not read (and, therefore, was not affected by) PLIVA’s
inadequate warning. In her deposition, plaintiff testified that she had never even heard of PLIVA prior to taking
metoclopramide, and further stated that, at no time, did she ever read any information about metoclopramide from
PLIVA. (Doc. No. 106-1 (Deposition of Eleanor Fulgenzi) at 5413.)
21

PDR for Reglan but did not know of risk of long-term use].) The one thing they all have in
common, however, is that they all prescribed Reglan, not the generic metoclopramide.12 (Ahmed
Dep. I at 3525; Sobolewski Dep. at 8246-47; Baranauskas Dep. at 8375, 8380, 8398-99.)
Whether or not they read the Reglan insert, which coincidently had the adequate warning that is
at issue in this litigation, the fact that they were prescribing the name-brand drug dictated that
they would have had no reason to seek out an insert from one of several manufacturers of the

12

Other courts have relied on this fact in applying the learned intermediary doctrine, as it exists in other state’s laws,
to dismiss similar cases brought against PLIVA and other manufacturers of metoclopramide. For example, in Bell v.
Pfizer, Inc., the Eighth Circuit addressed PLIVA’s failure to adopt the 2004 label change to its metoclopramide
product. The court began with the fact that, like here, the plaintiff’s “physician prescribed Reglan—not generic
metoclopramide manufactured by PLIVA.” 716 F.3d 1087, 1097 (8th Cir. 2013). It then added to it the fact that
plaintiff “admit[ted] that in prescribing Reglan, her physician relied on information published in the brand
defendants’ package inserts and/or Physicians’ Desk Reference . . . or otherwise disseminated by the brand
defendants.” Id. (quotation marks and citations omitted). The court found that these facts served to break the “causal
link” between the plaintiff’s injury and PLIVA’s failure to incorporate the 2004 label change. Id. at 1097-98.
(quotation marks and citation omitted); see, e.g., Fullington v. Pfizer, Inc., 720 F.3d 739, 747 (8th Cir. 2013) (“A
manufacturer’s inadequate warning is not a proximate cause of a plaintiff’s harm so long as the prescribing
physician had independent knowledge of the risk that the inadequate warning should have communicated.”) (citing
Bell, 716 F.3d at 1096-97).
In Brinkley v. Pfizer, Inc., the plaintiff attempted to distinguish Bell and Fullington by alleging that her
prescribing physician, who like the physicians in Bell and Fullington had prescribed the brand name Reglan (and not
the generic metoclopramide), was unaware of the 2004 warning contained in Reglan’s label. Brinkley, 772 F.3d
1133, 1138 (8th Cir. 2014). Finding this to be a distinction without a difference, the court reasoned: “[t]hat
[Brinkley] alleges her physician did not receive an adequate warning about Reglan does nothing to bridge the gap
between her injury and Pliva’s failure to update its label. Furthermore, whether from Pliva or the brand-name
manufacturer, the adequacy of the instructions . . . made no difference in the outcome of [Brinkley’s injury] because
[Brinkley alleges her prescribing physician] did not read those materials.” Id. at 1138-39 (quotation marks and
citation omitted).
Again, the record is clear that plaintiff’s physician’s wrote prescriptions for Reglan, and not generic
metoclopramide. (Ahmed Dep. I at 3525; Sobolewski Dep. at 8246-47; Baranauskas Dep. at 8375, 8380, 8398-99.)
The logic employed by courts, such as the Eighth Circuit, would dictate that this fact severs the casual connection
between PLIVA’s inadequate warning and plaintiff’s injuries as an adequate warning was available for the drug
plaintiff’s physicians prescribed, regardless of whether the physicians actually read it. However, the language of the
Ohio statute that codified this doctrine suggests that the otherwise adequate warning must come from the
manufacturer who supplied the drug in question. See Ohio Rev. Code § 2307.76(C). At a minimum, however, the
fact that plaintiff’s physicians prescribed the name brand drug further underscores the fact that PLIVA’s warning
could not be the proximate cause of plaintiff’s injuries. See, e.g., Pustejovsky, 623 F.3d at 277 (“As [plaintiff] cannot
demonstrate that PLIVA’s inadequate warning was the producing cause of her injury, the learned-intermediary
doctrine bars her recovery.”).
22

generic counterpart.13 While, at the end of the day, what matters is that the physicians did not
read or rely on PLIVA’s insert, the fact that the physicians prescribed the name-brand drug lends
further support to the conclusion that they did not rely on the package insert from PLIVA.
Apparently recognizing the factual disconnect between PLIVA’s inadequate 2004
warning label and her injuries, plaintiff suggests that “warnings and/or instructions can be
defective and inadequate based, not only upon its content, but also due to the manner in which
they are communicated . . . .” (Opp’n at 7928, emphasis added.) She further argues that PLIVA
“did nothing to communicate the information added to the metoclopramide label in 2004” and
“did not provide any warnings or instructions about its metoclopramide products to physicians at
all.” (Id. at 7928-29, emphasis and underlining in original). Plaintiff appears to be advancing the
position that PLIVA should have found some other way to communicate the information in the
2004 updated warning to plaintiff’s physicians. (See id. at 7928-29.) Such an argument is
preempted by Mensing.
The Sixth Circuit has recently rejected a similar “failure-to-communicate” theory
advanced against generic drug manufacturers. In In re Darvocet, Darvon, and Propoxyphene
Prods. Liab. Litig., 756 F.3d 917 (6th Cir. 2014), the plaintiffs argued that generic drug
manufacturers should have sent “Dear Doctor” letters directly to physicians to communicate
risks associated with the use of their prescription medication. In affirming the district court’s
dismissal of the action, the court cited decisions from other circuits rejecting such an argument

13

It is true that Dr. Ahmed testified in his deposition that he was aware that when he wrote the prescription for the
name-brand Reglan it might be filled with the generic form metoclopramide. (Ahmed Dep. at 8304-05.) But this
testimony alone cannot create a fact issue as to whether Dr. Ahmed read the PLIVA insert when there are numerous
manufacturers of the generic form of Reglan, this physician testified unequivocally that he did not read PLIVA’s
insert, and, in fact, had never even heard of PLIVA.
23

on the grounds that a generic manufacturer’s federal duty of “sameness” would prevent it from
independently pursuing any means of communication not utilized by the name-brand drug
manufacturer, as such unilateral action would inaccurately imply a therapeutic difference
between the brand name and its generic equivalent. Id. at 932-33 (citing Morris, 713 F.3d at 777;
Guarino v. Wyeth, LLC, 719 F.3d 1245, 1249 (11th Cir. 2013)); see Strayhorn v. Wyeth Pharm.,
Inc., 737 F.3d 378, 398 (6th Cir. 2013) (generic drug manufacturers were not permitted to send
“Dear Doctor” letters directly to physicians); see also Fulgenzi, 711 F.3d at 581 n.1 (federal
regulations provide that “labeling” includes not just the written label but also all communications
with physicians, including “Dear Doctor” letters).
Because the manufacturer of the brand name Reglan did not communicate the
content of the 2004 updated warning in any way other than by changing its label, the generic
manufacturers were not free to pursue other forms of communication to disseminate this
information. See Strayhorn, 737 F.3d at 398 (“Because no brand-name manufacturer sent a
warning based on the 2004 label change, the generic manufacturers were not at liberty to do so.”)
(quoting Morris, 713 F.3d at 777.) Thus, while PLIVA was required to update its label in 2004 to
match the change made by the manufacturer of Reglan, and plaintiff was permitted to pursue a
failure-to-warn claim based on PLIVA’s failure to make that change, any argument that PLIVA
should have pursued other forms of communication is foreclosed by Mensing.
Likewise, plaintiff’s argument that she can satisfy the proximate cause element of
her failure-to-warn claim solely with physician testimony that, if the 2004 warning had been
brought to their attention it would have impacted their decision to prescribe Reglan to plaintiff,
suffers from the same deficiency. The generic drug manufacturers were under no duty to find
alternative means of bringing the warning to the attention of plaintiff’s physicians, and, in fact,
24

federal duty of “sameness” would actually have prevented it. The system put in place by
Congress dictates the means and methods by which generic drug manufacturers may
communicate warnings and label changes to physicians; a system that relies on physicians to
read the warnings included in package inserts. That there may have been a more effective way to
communicate this information to physicians is of no moment, and neither alters PLIVA’s
prescribed avenue for communicating with physicians, nor changes the fact that the prescribing
physicians did not see (and therefore could not be impacted by) PLIVA’s inadequate 2004
package insert in prescribing the medication for plaintiff.
Regardless of where the prescribing physicians obtained their information about
Reglan/metoclopramide, or how they came to decide that it should be prescribed to plaintiff, the
record is bereft of evidence that any of the physicians read PLIVA’s inadequate warning.
Consequently, an adequate warning from PLIVA would not have impacted any of the
physician’s decisions to prescribe Reglan to plaintiff. Ultimately, plaintiff’s failure to
demonstrate genuine issues of material fact as to the proximate cause of her injuries requires this
Court to grant PLIVA summary judgment.
IV. CONCLUSION
For all of the foregoing reasons, defendant PLIVA’s motion for summary
judgment (Doc. No. 102) is granted. This case is dismissed.
IT IS SO ORDERED.

Dated: October 23, 2015
HONORABLE SARA LIOI
UNITED STATES DISTRICT JUDGE

25